Advertisement
Advertisement
U.S. Markets open in 4 hrs 41 mins
Advertisement
Advertisement
Advertisement
Advertisement

DiaMedica Therapeutics Inc. (DMAC)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.8400+0.0300 (+1.66%)
At close: 04:00PM EDT
1.8900 +0.05 (+2.72%)
After hours: 05:04PM EDT
Advertisement

DiaMedica Therapeutics Inc.

Two Carlson Parkway
Suite 260
Minneapolis, MN 55447
United States
763 612 6755
https://www.diamedica.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees14

Key Executives

NameTitlePayExercisedYear Born
Mr. Dietrich John Pauls MBAPres, CEO & Director684.09kN/A1971
Mr. Scott B. Kellen C.A.CFO & Company Sec.391.72kN/A1965
Dr. Edward G. Calamai Ph.D.Consulting Head of ManufacturingN/AN/AN/A
Dr. Kirsten L. Gruis M.D., M.S.Chief Medical OfficerN/AN/A1973
Mr. Dominic R. CundariChief Commercial OfficerN/AN/A1951
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Corporate Governance

DiaMedica Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement